AXL Receptor in Breast Cancer: Molecular Involvement and Therapeutic Limitations.
AXL Receptor in Breast Cancer: Molecular Involvement and Therapeutic Limitations.
复制标题
DOI:
10.3390/ijms21228419
复制
发表时间:
2020-11-10
影响因子:
5.6
通讯作者:
Ciuffreda L
中科院分区:
文献类型:
--
作者:
Falcone I;Conciatori F;Bazzichetto C;Bria E;Carbognin L;Malaguti P;Ferretti G;Cognetti F;Milella M;Ciuffreda L
Breast cancer was one of the first malignancies to benefit from targeted therapy, i.e., treatments directed against specific markers. Inhibitors against HER2 are a significant example and they improved the life expectancy of a large cohort of patients. Research on new biomarkers, therefore, is always current and important. AXL, a member of the TYRO-3, AXL and MER (TAM) subfamily, is, today, considered a predictive and prognostic biomarker in many tumor contexts, primarily breast cancer. Its oncogenic implications make it an ideal target for the development of new pharmacological agents; moreover, its recent role as immune-modulator makes AXL particularly attractive to researchers involved in the study of interactions between cancer and the tumor microenvironment (TME). All these peculiarities characterize AXL as compared to other members of the TAM family. In this review, we will illustrate the biological role played by AXL in breast tumor cells, highlighting its molecular and biological features, its involvement in tumor progression and its implication as a target in ongoing clinical trials.
登录
查看更多内容
影响因子:
16.6
作者:
通讯作者:
--
影响因子:
37.3
作者:
Du Z;Lovly CM
通讯作者:
Lovly CM
影响因子:
8
作者:
通讯作者:
--
DOI:
10.1073/pnas.0909333107
发表时间:
2010-01-19
影响因子:
11.1
作者:
Gjerdrum, Christine;Tiron, Crina;Lorens, James B.
通讯作者:
Lorens, James B.
影响因子:
11.2
作者:
Abba, Martin C.;Fabris, Victoria T.;Aldaz, C. Marcelo
通讯作者:
Aldaz, C. Marcelo